Sun Jiajing, Wu Sikai, Jin Zixian, Ren Sijia, Cho William C, Zhu Chengchu, Shen Jianfei
Taizhou Hospital, Zhejiang University, Taizhou, China.
Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, China.
Biomed Pharmacother. 2022 May;149:112817. doi: 10.1016/j.biopha.2022.112817. Epub 2022 Mar 15.
Lung cancer has some of the highest morbidity and mortality rates of all cancers, and an important risk factor for mortality in patients with lung cancer is tumor metastasis. Even if a tumor is completely removed at an early stage of the disease, quite a number of patients still have the risk of recurrence. With the advent of molecular diagnostic and therapeutics, more and more studies have found that a poor prognosis may be related to lymph node micrometastasis. However, clinicians still find that predicting the prognosis and choosing the type of surgery and postoperative adjuvant chemotherapy are still challenging. Thus, this article reviews the current research status of lymph node micrometastasis in non-small cell lung cancer, envision to provide some updates and insights in this area.
肺癌是所有癌症中发病率和死亡率最高的癌症之一,肺癌患者死亡的一个重要风险因素是肿瘤转移。即使在疾病早期肿瘤被完全切除,仍有相当数量的患者存在复发风险。随着分子诊断和治疗方法的出现,越来越多的研究发现预后不良可能与淋巴结微转移有关。然而,临床医生仍然发现预测预后以及选择手术类型和术后辅助化疗仍然具有挑战性。因此,本文综述了非小细胞肺癌淋巴结微转移的当前研究现状,以期在该领域提供一些新的进展和见解。